A significant fraction of pharma and biotech pipelines are comprised of poorly soluble and, hence, poorly bioavailable compounds. Amorphous solid dispersions (ASDs) are a proven technology that have been commercialized in over twenty products. Key to progressing ASDs is the use of rapid, bulk-sparing methods to characterize ASD performance and identify commercially relevant formulations early, and avoid re-formulation later in the project lifecycle. This talk focuses on identification of methods for predicting ASD performance and case studies for poorly soluble molecules. To learn more, watch our on-demand presentation.
Content Type: Presentation (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center